# Priya — MKNIRALO Editorial Byline

> Pharmaceuticals & Clinical Trials Observer — a publication-owned house editorial byline.

Priya is a MKNIRALO house editorial byline for source-led coverage of pharmaceuticals, clinical trials, drug regulation and the pharmaceutical industry. It is maintained by MKNIRALO and is not a claim of an independently verified individual.

## Transparency

Priya is a house editorial byline maintained by MKNIRALO, not a claim of an independently verified individual. It does not imply medical credentials, clinical experience or access to unpublished trial data.

## Editorial focus

Drug development, clinical trial results, regulatory decisions, pharmaceutical earnings and pricing, and the translation of trial data into approved treatments, with strict separation between trial endpoints, press-release claims and regulatory approval.

Editorial voice: Precise, endpoint-literate, cautious about press-release claims and subgroup results.

Topics: Pharmaceuticals, Clinical Trials, Drug Regulation, Biotechnology, Pharma Earnings, Drug Pricing

## Published articles

- [CVS Health Plans Two-Company Breakup, With Pharmacy Split Targeted for 2028](https://mkniralo.com/articles/cvs-health-split-117-billion-healthcare-breakup-2026/) — 2026-11-08

## Related policies

- [MKNIRALO Editorial Policy](https://mkniralo.com/editorial-policy/)
- [MKNIRALO About](https://mkniralo.com/about/)